Leishmania donovani in hamsters: stimulation of non-specific resistance by some novel glycopeptides and impact on therapeutic efficacy.
Several glycopeptides structurally related to muramyl dipeptide (MDP) have been synthesized and evaluated for their ability to stimulate the non-specific resistance of hamsters against L. donovani infection. These compounds have been named CDRI compounds. The synthetic procedure used for compounds 86/448 and 84/212 is described. MDP and its synthetic congeners were administered as immunostimulants at a prophylactic dose of 3 mg/kg at two weeks interval. The challenge infection (1 x 10(7) amastigotes i.c./hamster) was given in between two doses of the compounds. One of the glycopeptides, CDRI comp. 86/448, has been found to be significantly more potent than MDP, effecting 92% inhibition of the challenge dose, whereas MDP produced only 26.5% inhibition. The effect of comp. 86/448 lasted until day 7 of challenge. The efficacy of sodium stibogluconate was appreciably improved in hamsters treated with comp. 86/448.
Pal
R
R
Division of Parasitology, Central Drug Research Institute, Lucknow, India.
Anuradha
Rizvi
S Y
SY
Kundu
B
B
Mathur
K B
KB
Katiyar
J C
JC
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology*; D000595:Amino Acid Sequence; D000818:Animals; D006224:Cricetinae; D004353:Drug Evaluation, Preclinical; D007113:Immunity, Innate / Q000187:drug effects; D007893:Leishmania donovani / Q000187:drug effects*; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000276:immunology; D008969:Molecular Sequence Data
D000119:Acetylmuramyl-Alanyl-Isoglutamine